Results 261 to 270 of about 61,117 (342)

Mineralocorticoid receptor knockout alters hippocampal CA2 neurons to become like those in CA1. [PDF]

Commun Biol
Harris EP, Kandemir B, Jones SM, Alexander GM, Ward JM, Wang T, Proaño S, Xu X, Dudek SM.   +8 more
europepmc   +1 more source

Effects of a non-steroidal selective of mineralocorticoid receptor antagonist, on blood pressure on hypertension and renal injury in low-renin salt-sensitive hypertensive rats

, 2019
Akira Nishiyama, Daisuke Nakano, Lei Li
openalex   +2 more sources

Proteins and signalling pathways targeted by dapagliflozin and finerenone: Insights from DAPA‐CKD and FIGARO‐DKD

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 750-753, January 2026.
Mark André de la Rambelje, Adriaan A. Voors, Peter J. Greasley, Mario Berger, Hiddo J. L. Heerspink   +4 more
wiley   +1 more source

Intracavernous Injection of Mechanically Extracted Stromal Vascular Fragments Suppresses Endothelial‐Mesenchymal Transformation to Mitigate Erectile Dysfunction in Hypertensive Rats

Stem Cells International, Volume 2026, Issue 1, 2026.
Erectile dysfunction (ED) is widespread among individuals with high blood pressure and negatively affects quality of life. The effect of stromal vascular fraction (SVF) on hypertension‐related ED remains unexplored. We used a hypertensive rat model to explore the relative efficacy of adipose tissue stromal vascular fraction (tSVF) and cellular SVF ...
Cheng Shao, Yi Sun, Jun Zhao, Chao Ju, Tianli Yang, Jingyu Liu, Liuhua Zhou, Ruipeng Jia, Feng Zhao, Harleen Khatra   +9 more
wiley   +1 more source

An individual treatment effect approach to predict response to mineralocorticoid receptor antagonists in patients with heart failure and reduced ejection fraction. [PDF]

Eur J Heart Fail
Kobayashi M, Duarte K, Ferreira JP, Baudry G, Monzo L, McMurray JJV, Van Veldhuisen DJ, Pitt B, Zannad F, Girerd N.   +9 more
europepmc   +1 more source

Prostaglandin D₂ Synthase: A Novel Player in the Pathological Signaling Mechanism of the Aldosterone-Mineralocorticoid Receptor Pathway in the Heart. [PDF]

Cells
Garg A, Juchem M, Biss S, Borisch CN, Leonardy J, Bär C, Gupta SK, Thum T.   +7 more
europepmc   +1 more source

Initiation of SGLT2 inhibitors versus mineralocorticoid receptor antagonists as third-line therapy in heart failure with reduced ejection fraction: a nationwide cohort study. [PDF]

Lancet Reg Health Eur
Svanström H, Mkoma GF, Hviid A, Pasternak B.   +3 more
europepmc   +1 more source

Clinical implications of mineralocorticoid receptor overactivation. [PDF]

Clin Kidney J
El Mouhayyar C, Chhikara M, Tang M, Nigwekar SU.   +3 more
europepmc   +1 more source

Efficacy and safety of mineralocorticoid receptor antagonists in kidney transplant patients: an updated meta-analysis of randomized controlled trials. [PDF]

BMC Nephrol
Dibo P, Mareddy NSR, Kojima GSA, Ershed M, Obi OS, Razaq S, Kumar V.   +6 more
europepmc   +1 more source